SGLT2在1型糖尿病合并糖尿病肾病中的抑制作用：潜在的心肾益处可能超过糖尿病酮症酸中毒的可预防风险

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Current Diabetes Reports Pub Date : 2022-05-28 DOI:10.1007/s11892-022-01471-2

Hongyan Liu, V. Sridhar, B. Perkins, J. Rosenstock, D. Cherney

引用次数: 3

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

查看原文本刊更多论文

SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.